cinepazide

Phase 2Small molecule

XXijing Hospital

cinepazide is one of 28 small molecule programs targeting Cerebral Infarction. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral InfarctionActive, not recruiting

Cerebral InfarctionPhase 2

Active, not recruiting

Competition

Competitive Landscape

44 competitors in Cerebral Infarction

#DrugCompanyPhaseTrials

Lorelco

Sanofi

Approved

1 2

Plavix

Sanofi

Approved

1 3

Prevacid

Takeda

Approved

—4

Nimotop

AAzurity Pharmaceuticals

Approved

1 5

Gocovri

GGrupo Espanol de Tumores Neuroendocrinos

Bayer Aspirin

2 7

Activase

Pletal

1 9

Neo-Synephrine

EExela Pharma Sciences, LLC.

Phase 3

1 10

Xe-133

NNobilis Therapeutics Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cerebral Infarction1 trial

Methanesulfonic Acid Cinepazide Injection for Treatment of Acute Cerebral Infarction

Unknown status·XXijing Hospital·Phase 2·NCT01851759·288 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for cinepazide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cinepazide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cinepazide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xijing Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: XXijing Hospital

cinepazide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cerebral Infarction1 trial

References

Drug Info

Quick Facts

Related News